医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ReNAgade to Present at the Upcoming 42nd Annual J.P. Morgan Healthcare Conference

2024年01月04日 PM10:00
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, Mass.

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 8:30 a.m. PT in San Francisco, CA.

About ReNAgade Therapeutics

ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.

To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.

ReNAgade Therapeutics—RNA Without Limits

For more information about the company, its technologies, and its leadership, visit www.renagadetx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240104374758/en/

CONTACT

Investor Relations:

Emily Brabbit, Argot Partners

(212) 600-1902

renagade@argotpartners.com

Media Relations:

Sarah Sutton, Argot Partners

(212) 600-1902

renagade@argotpartners.com

同じカテゴリーの記事 

  • KCAS Bio and Crux Biolabs Announce Global Spectral Flow Cytometry Alliance
  • Firstsource Acquires Quintessence
  • Dr. Reddy’s Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
  • パース・バイオサイエンシズ、シングル・セル免疫プロファイリング製品を発表
  • Parse Biosciences推出单细胞免疫分析产品